Divalproex Sodium Tablet, Extended Release
Product Images NDC 50268-259

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50268-259). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

50 (259 15)

50 (259 15)
NDC 50268-259-15 is a prescription medication for Divalproex Sodium and it comes in extended-release tablets. The tablets can be taken once-daily and each tablet contains 250mg of the active ingredient. The medication is used for treating seizures, bipolar disorder, and migraines. Dosage and storage instructions are also available.*
FDA Label Image

30 (260 13)

30 (260 13)
This is a description of medication in tablet form, with a specific identification number: NDC 50268.260-13. The tablet contains 500mg of Divalproex Sodium in an extended-release formula, and comes in a container with 30 tablets, with instructions for a once-daily dose. The drug is only available by prescription and should be stored within a temperature range of 20 to 25 degrees Celsius. The dosage instructions are intended for prescribers and the container carries identification numbers.*
FDA Label Image

10 (Divalproex Sodium Extended Release Tablets Usp 1)

10 (Divalproex Sodium Extended Release Tablets Usp 1)
FDA Label Image

Figure 1 (Divalproex Sodium Extended Release Tablets Usp 2)

Figure 1 (Divalproex Sodium Extended Release Tablets Usp 2)
FDA Label Image

Figure 2 (Divalproex Sodium Extended Release Tablets Usp 3)

Figure 2 (Divalproex Sodium Extended Release Tablets Usp 3)
The text appears to be a chart or graph representing the percentage reduction in CPS rate for high dose and low dose divalproex sodium. The chart shows the percentage of patients who experienced improvement, no change, or worsening in their condition. However, without additional context, it is difficult to provide a more specific description.*
FDA Label Image

Figure 3 (Divalproex Sodium Extended Release Tablets Usp 4)

Figure 3 (Divalproex Sodium Extended Release Tablets Usp 4)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.